Histogenics Corporation Provides NeoCart® Phase 3 Clinical Trial Enrollment Update
October 24, 2016 08:30 ET
|
Histogenics Corporation
WALTHAM, Mass., Oct. 24, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the...
Histogenics Corporation to Ring the Nasdaq Stock Market Closing Bell
October 13, 2016 08:30 ET
|
Histogenics Corporation
WALTHAM, Mass., Oct. 13, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the...
Histogenics Corporation Announces Addition of Dr. Lawrence Bonassar of Cornell University to Its Scientific Advisory Board
October 06, 2016 16:05 ET
|
Histogenics Corporation
- Company Adds Additional Leader in Tissue Engineering and Biomechanics -- Additional NeoCart® Biomechanical Data Presented in Conjunction with Cornell University - WALTHAM, Mass., Oct. 06, 2016 ...
Histogenics Corporation Closes $30.0 Million Private Placement
September 29, 2016 16:05 ET
|
Histogenics Corporation
WALTHAM, Mass., Sept. 29, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the...
Histogenics Corporation to Present at the 2016 Cell & Gene Meeting on the Mesa
September 26, 2016 08:30 ET
|
Histogenics Corporation
WALTHAM, Mass., Sept. 26, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the...
Histogenics Corporation Announces $30.0 Million Private Placement
September 16, 2016 06:30 ET
|
Histogenics Corporation
WALTHAM, Mass., Sept. 16, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the...
Histogenics Corporation to Present at the 18th Annual Rodman & Renshaw Global Investment Conference
August 31, 2016 08:30 ET
|
Histogenics Corporation
WALTHAM, Mass., Aug. 31, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the...
Histogenics Corporation Announces Second Quarter 2016 Financial and Operating Results
August 11, 2016 06:30 ET
|
Histogenics Corporation
- NeoCart® Phase 3 Clinical Trial Remains on Track for Enrollment Completion by End of Second Quarter of 2017 - - Increasing Year-End 2016 Enrollment Guidance to 190 to 200 patients...
Histogenics Corporation to Announce Second Quarter 2016 Financial Results on August 11, 2016
July 28, 2016 08:30 ET
|
Histogenics Corporation
WALTHAM, Mass., July 28, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal...
Histogenics Corporation to Present at the Canaccord Genuity Growth Conference
July 27, 2016 08:30 ET
|
Histogenics Corporation
WALTHAM, Mass., July 27, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the...